Last reviewed · How we verify
Comparator: paroxetine HCL
Paroxetine HCl selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Paroxetine HCl selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Comparator: paroxetine HCL |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. It has minimal effects on other neurotransmitter systems compared to older antidepressants.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Social anxiety disorder
Common side effects
- Nausea
- Headache
- Insomnia
- Somnolence
- Sexual dysfunction
- Tremor
- Diarrhea
- Sweating
Key clinical trials
- Influence of Oxycodone on Individuals Taking an SSRI (PHASE1)
- Treatment of Tinnitus With Migraine Medications (PHASE4)
- Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (PHASE4)
- Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD) (PHASE2)
- Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) (PHASE4)
- Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers (PHASE1)
- A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder (PHASE1)
- Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: paroxetine HCL CI brief — competitive landscape report
- Comparator: paroxetine HCL updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI